$INSP

Inspire Medical Systems, Inc.

Inspire Medical Systems develops and commercializes minimally invasive treatments for obstructive sleep apnea. Its main product is the Inspire system, an implantable neurostimulation device for eligible patients with moderate to severe OSA who cannot tolerate or have not benefited from PAP treatment in certain markets. The system monitors breathing and stimulates the hypoglossal nerve to help keep the airway open. Related offerings include the SleepSync™ cloud-based patient management platform, a clinician programmer, a patient remote control and smartphone app, and the Inspire Advisor Care Program, which helps patients connect with healthcare providers. Inspire sells its system to hospitals and ambulatory surgery centers through a direct sales force in the U.S., Europe and Japan, and through distributors in Singapore, Hong Kong and Thailand. It earns money by selling the system; treatment is generally reimbursed by third-party payors in the U.S. Inspire Medical Systems is headquartered in Golden Valley, Minnesota.

0
0
1

No SEC Form 4 filings for $INSP in the last 30 days.

See all $INSP insider activity →

INSP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning INSP (Inspire Medical Systems, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent INSP coverage spans financial news and earnings.

What's driving INSP

AlphAI scores every news story that mentions INSP with an AI model for sentiment and relevance, and aggregates insider trades from Inspire Medical Systems, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $INSP

Score

Truist cuts Inspire Medical Systems stock price target on revenue outlook

Truist Securities reduced its price target for Inspire Medical Systems (NYSE:INSP) to $76 from $78, citing a revised 2028 revenue estimate of $937M. The stock trades at $67.21, considered undervalued. Q3 2026 results beat estimates, with revenue at $206.7M and EPS at $0.14. Wells Fargo raised its target to $69. Growth is expected to re-accelerate to low-single to mid-single digits in 2027-2028.

$INSPHighAI 8/10

Inspire Medical Q3 2026 slides: reimbursement clarity ahead, growth reset

Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3.0% sequentially. The company cited reimbursement challenges as the primary headwind. Shares rose 1.83% in after-hours trading. Inspire highlighted its market position and long-term growth potential, despite near-term slowdowns. The company expects full-year 2026 revenue of $850M-$860M, down from 2025 levels.

Related tickers